Patients and families affected by Duchenne have different treatment goals depending on the stage and severity of their disease. In order to improve care, accelerate drug development, and expedite access to approved treatments for all, it is important to identify patient and caregiver concepts of interests that go beyond the clinical outcome assessments being measured in most Duchenne clinical trials and have monolithic treatment objectives.